Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open label, repeated dose, range finding study to evaluate the
safety, tolerability, immunogenicity, pharmacokinetics and efficacy of ACZ885, a fully human
anti-interleukin-1B (anti-IL-1B) monoclonal antibody, given subcutaneously in pediatric
subjects with active SJIA.